The Moment Everything Changed: First Patient Dosed AMG 510 August 2018
There's a particular kind of quiet that surrounds a moment like this. But aMG 510 wasn't just another drug candidate entering Phase 1 testing. In August 2018, the first patient was dosed AMG 510, and most of the world didn't notice. Worth adding: it was the first molecule built to do what decades of cancer research said was impossible — hit a target that had been written off as undruggable. But inside the walls of clinical trial sites and Amgen's research campuses, something had just shifted irreversibly. And the fact that it finally reached a human being marked the end of one era and the beginning of another Most people skip this — try not to..
Here's what happened, why it mattered then, and why it still matters today And that's really what it comes down to..
What Is AMG 510?
AMG 510 is a small molecule inhibitor designed to target a specific mutation in the KRAS protein — the KRAS G12C variant. To understand why that's a big deal, you need a little context about KRAS itself.
KRAS is a gene that produces a protein involved in sending signals that tell cells to grow and divide. Still, when KRAS mutates, those signals get stuck in the "on" position, and cells divide uncontrollably. KRAS mutations are found in roughly 25% of all cancers, and they're especially prevalent in pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer.
For years, KRAS was the poster child of the "undruggable" target. On top of that, the protein lacks a deep binding pocket — the kind of crevice that most drugs need to latch onto and shut down a malfunctioning protein. Drug designers tried and failed for decades. The scientific consensus, as blunt as it sounds, was that you simply couldn't make a drug that worked against KRAS.
Then, in 2013, a team at the University of California, San Francisco published research showing that a specific mutation — G12C — actually created a new, previously hidden pocket near the switch-II region of the KRAS protein. That pocket was small and fleeting, but it was there. And it was enough.
Amgen, the biotechnology company behind the molecule, ran with it. The result was AMG 510: a covalent inhibitor designed to slip into that pocket and lock KRAS G12C in its inactive, GDP-bound state Less friction, more output..
The Chemistry Behind the Breakthrough
The drug works by exploiting a unique feature of the G12C mutation. In normal KRAS, the glycine at position 12 allows the protein to flex freely between its active and inactive states. When that glycine is replaced by cysteine, a new pocket opens up — and AMG 510 is engineered to bind covalently to that cysteine residue. Once bound, the protein stays frozen in the off position. No growth signal. No uncontrolled division.
This is a structure-based drug design story, and it's one of the best examples of how understanding protein architecture at the atomic level can translate directly into a therapeutic strategy.
Why It Matters: The First Patient Dosed AMG 510 August 2018
The first patient dosed AMG 510 in August 2018 wasn't just a logistical milestone — a checkmark on a clinical trial timeline. It represented the culmination of years of painstaking work, from the initial discovery of the cryptic pocket to the optimization of the molecule's pharmacokinetics and safety profile.
What Happened in That First Dose
The Phase 1 clinical trial, known as the CodeBreaK trial, enrolled patients with advanced solid tumors harboring the KRAS G12C mutation. Now, these were patients who had exhausted standard treatment options. Many had tried multiple lines of chemotherapy, immunotherapy, and targeted therapy. For them, AMG 510 represented a last — or in some cases, a first — chance at a mechanism-based therapy Simple, but easy to overlook..
The dose escalation phase proceeded with the standard caution of early-phase oncology trials. Researchers started low and worked upward, monitoring for safety signals, pharmacokinetic behavior, and any hint of tumor response. And slowly, the data began to come in.
Early Signals of Activity
Even in those early cohorts, the results were striking. Consider this: symptoms improved. Some patients with heavily pretreated lung cancers and colorectal cancers showed objective responses to AMG 510 monotherapy. Tumors shrank. And perhaps most importantly, the responses appeared durable — lasting weeks or months in patients who had been told there were no further options.
Worth pausing on this one.
These early signals were enough to generate excitement in the oncology community, but they were also just the beginning. The real validation would come in larger trials, with more patients, and with longer follow-up.
How KRAS G12C Inhibition Changed the Oncology Landscape
The success of AMG 510 opened the floodgates. If KRAS G12C could be drugged, what else had been dismissed? The answer turned out to be: more than anyone expected Worth knowing..
The Wave of Competitors
Following Amgen's lead, multiple pharmaceutical companies accelerated their own KRAS G12C programs. Adagrasib (MRTX849) from Mirati Therapeutics, and later sotorasib (Lumakras), became the most prominent competitors. Sotorasib, in fact, became the first KRAS G12C inhibitor to receive FDA approval, in May 2021, for the treatment of advanced NSCLC And that's really what it comes down to..
AMG 510 itself was eventually codenamed sotorasib and became the first approved KRAS G12C inhibitor — a full circle moment that traced its origin back to that first patient dosed in August 2018.
Expanding Beyond NSCLC
While early responses were most dramatic in non-small cell lung cancer, researchers quickly began exploring AMG 510 and its peers in other KRAS G12C-mutant cancers. Colorectal cancer proved more challenging due to mechanisms of resistance, including rapid clearance of the drug through the hepatobiliary system and feedback activation of upstream signaling pathways. But the effort to overcome these resistance mechanisms has itself become a rich area of investigation.
Combination strategies — pairing KRAS G12C inhibitors with SHP2 inhibitors, MEK inhibitors, or immune checkpoint inhibitors — are now being tested in multiple clinical trials. The idea is straightforward: block the oncogene directly, while simultaneously cutting off the escape routes that tumors use to survive.
What Most People Get Wrong About AMG 510 and KRAS Drug Development
There are several misconceptions that circulate around this story, and they're worth addressing directly.
It Wasn't a Single "Eureka" Moment
The discovery of the cryptic pocket in 2013 was important, but it wasn't the whole story. Turning that structural insight into a clinically viable drug required years of medicinal chemistry, preclinical toxicology, formulation work, and regulatory navigation. The first patient dosed AMG 510 August 2018 was the result of a long, unglamorous chain of decisions, experiments, and iterations.
It Didn't Cure KR
AS Mutations
A common misconception is that the development of AMG 510 meant the "war on KRAS" was won. Here's the thing — tumors are notoriously adaptive; many patients eventually develop secondary mutations in the KRAS protein itself or activate alternative signaling pathways that bypass the drug's inhibitory effects. While these drugs have provided a lifeline to many, they are not a universal panacea. That's why in reality, the success of G12C inhibitors has merely shifted the battlefield. The victory was not in eradicating the mutation, but in proving that the "undruggable" target could be successfully engaged Turns out it matters..
It’s Not Just About the Molecule
There is also a tendency to view drug development as a race to find the "perfect" molecule. The development of these inhibitors required a deep understanding of the protein's conformational states—specifically the "on" and "off" switches. While the potency of AMG 510 was critical, the clinical success of the KRAS class was equally dependent on understanding the biology of the disease. Without this structural biology foundation, even the most potent chemical compound would have failed to find its target in a living system Simple, but easy to overlook..
The Road Ahead: Precision Medicine 2.0
As we look toward the future, the legacy of AMG 510 will likely be measured by how it paved the way for the next generation of precision oncology. We are moving away from a "one size fits all" approach toward a landscape defined by molecular granularity.
The next frontier involves targeting other KRAS variants, such as G12D and G12V, which are prevalent in pancreatic and colorectal cancers but were previously thought to be inaccessible. On top of that, the rise of proteolysis-targeting chimeras (PROTACs)—which don't just inhibit the KRAS protein but actually trigger its degradation—represents a potential paradigm shift that could render traditional inhibitors obsolete That's the part that actually makes a difference..
In the long run, the story of AMG 510 is a testament to the resilience of scientific inquiry. In practice, it is a reminder that in oncology, "undruggable" is not a permanent status, but a temporary challenge. As our tools for structural biology and genomic sequencing continue to evolve, the boundaries of what we can treat will continue to expand, turning once-impossible targets into standard-of-care therapies.
